Esperion Therapeutics
Ben has been their Chief Financial Officer since 2022. He was promoted to the CFO role after serving several years as Esperion’s Senior Director, Financial Planning and Analysis where he oversaw the financial planning and analytics team and partnered with executive leadership and the commercial organization to help the company manage its financial goals. Prior to joining Esperion, Ben held financial and business roles of increasing responsibility with National Oilwell Varco, BMC Software, and Pfizer.
Ben holds a Bachelor of Arts in History from Syracuse University and a Master in Business Administration from Fordham’s Gabelli School of Business.
This person is not in any offices
Esperion Therapeutics
2 followers
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at ESPERION is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.